Cedars-Sinai Medical Center

Piotr Slomka

Sebastien Cadet

Rajendra Makkar

Damini Dey

Paul Kavanagh

Tejas Parekh

Assessment of transthyretin amyloid cardiomyopathy (ATTR-CM) can be performed by calculating a cardiac pyrophosphate activity (CPA) measurement from single-photon emission computed tomography (SPECT) images. SPECT images obtained usingTechnetium-pyrophosphate as a radiotracer can be analyzed to calculate CPA. Scan-specific thresholds for abnormal myocardial activity are identified based on left ventricular blood pool (LVBP) radiotracer counts, then radiotracer activity in regions of the myocardium with abnormal myocardial activity is determined. Finally, a CPA measurement can be calculated as a function of the mean radiotracer counts in such regions over the maximal LVBP radiotracer activity multiplied by the volume of involvement (e.g., the volume of abnormal activity). This CPA measurement can then be used as an assessment of ATTR-CM.

Systems and methods for the assessment of cardiac amyloidosis

Calcific and noncalcific aortic tissue components can be quantified. Pre-intervention planning computed tomography angiography imaging data is received. A region of interest is defined between the lower coronary ostium and the virtual basal ring. Cross-sectional images of the region of interest are rendered and calcific and noncalcific tissue components are identified based on Hounsfield unit thresholds. The volumes of the identified calcific and noncalcific tissue components are calculated and used to determine a total tissue volume (e.g., fibrocalcific volume) for the valve, as well as component percentages of the total tissue volume for the calcific and noncalcific components. These volumes and/or component percentages can be leveraged to predict severe AS, identify prognosis of post-TAVI outcomes, or otherwise facilitate planning of medical intervention.

Growing community of inventors

Los Angeles, CA, United States of America

Piotr Slomka